Identification and Preclinical Pharmacology of the -Secretase Modulator BMS-869780

Table 5

Summary of exposure in rat 4-day dosing experiment.

Dose; (mg/kg)	Male		Female
	Day 1	Day 3	Day 1	Day 3
	𝐶max (𝜇M)
10	2.0 (±0.4)	1.9 (±0.46)	2.9 (±0.4)	2.6 (±0.06)
30	6.1 (±1.8)	10.4 (±2.0)	8.2 (±1.7)	14.4 (±1.0)
100	7.7 (±0.9)	13.2 (±1.5)	10.6 (±1.0)	15.5 (±2.3)
	AUC (0–24 h) (𝜇M·h)
10	20.2 (±4.8)	17.5 (±5.7)	41.0 (±5.6)	25.0 (±1.5)
30	95.2 (±19.9)	128.6 (±65.0)	152.2 (±21.0)	255.1 (±28.5)
100	167.5 (±14.5)	216.9 (±80.5)	205.9 (±43.2)	316.4 (±77.0)
	𝑇max (h)
10	5.0 (±2.0)	5.0 (±2.0)	7.0 (±2.0)	5.0 (±2.0)
30	8.0 (±0.0)	3.0 (±1.0)	5.0 (±2.0)	3.0 (±1.0)
100	19.0 (±9.0)	7.0 (±2.0)	24 (±0.0)	4.0 (±4.0)
Dose; (mg/kg)	Terminal concentration day 4 (𝜇M)
	Male		Female
10	2.4 (±0.6)		3.0 (±0.3)
30	8.9 (±1.9)		12.0 (±4.6)
100	9.2 (±3.2)		13.7 (±0.9)